Skip to content
OpenCapital
Get started

Lantheus Holdings LNTH Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Cardinal Health logo
Cardinal HealthCAH
——

Other financials

Income statement

See full
Revenue$377.3M+1.2%
Gross profit$230.9M-2.9%
Operating income$81.3M-20.3%
Net income$118.4M+62.3%
EPS (diluted)$1.80+76.5%

Balance sheet

See full
Cash & equivalents$500.3M-46.8%
Total debt$627.9M+1.8%
Total equity$1.2B+4.1%
Total assets$2.3B+14.2%

Cash flow

See full
Operating cash flow$125.1M+16.3%
CapEx$3.2M-63.0%
Free cash flow$121.9M+23.3%

Valuation

See full
Market cap$6.76B-26.3%
Enterprise value$6.89B-20.5%
P/E24.2×-10.2×
P/S4.4×-1.6×

Profitability

See full
Gross margin60.5%-3.6pp
Operating margin18.8%-10.7pp
Net margin18%+0.7pp
FCF margin24.4%-6.4pp

Returns & leverage

See full
Return on equity23.5%-1.7pp
Debt / equity0.5×0.0×
Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: Lantheus Holdings’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lantheus Holdings's indefinite-lived research and development assets?
Lantheus Holdings (LNTH) reported indefinite-lived research and development assets of $6.19M in Q4 2025.
How has Lantheus Holdings's indefinite-lived research and development assets changed year-over-year?
Lantheus Holdings's indefinite-lived research and development assets decreased by 79.2% year-over-year, from $29.8M to $6.19M.
What is the long-term trend for Lantheus Holdings's indefinite-lived research and development assets?
Over 4 years (2020 to 2025), Lantheus Holdings's indefinite-lived research and development assets has grown at a -54.8% compound annual growth rate (CAGR), from $148.44M to $6.19M.
What does indefinite-lived research and development assets mean?
This represents the carrying value of acquired in-process research and development projects that have not yet reached commercial viability. These assets are not amortized but are subject to periodic impairment testing until the underlying projects are completed or abandoned. It serves as a key indicator of the company's investment in future product pipelines and long-term innovation potential.